Point-of-care testing: the views of the working group of the Dutch Association of Clinical Chemistry.
There is clearly a demand for near-patient laboratory testing. Modern technological developments support its implementation, but these are not the only preconditions that need to be satisfied in order to successfully introduce decentralized testing. In part 2 of this paper we give a definition of decentralized testing. Part 3 presents the advantages and disadvantages. This list is a summary taken from the suggested literature. Part 4 examines the formal position of the clinical chemist. Of major importance to the situation in the Netherlands are the Care Institutions Quality Act and the Individual Health Care Professions Act. Part 5 discusses professional standards. Part 6 outlines practical considerations which might support the implementation of decentralized testing. The clinical chemist should play an active role in drawing up a discussion paper for his own hospital.
Janssen
H W
HW
Department of Clinical Chemistry and Haematology, St. Franciscus Gasthuis, Rotterdam, The Netherlands. hansvjanssen@franciscus.nl
Bookelman
H
H
Dols
J L
JL
Gerritzen
W E
WE
de Keyzer
R H
RH
D002624:Chemistry, Clinical / Q000331:legislation & jurisprudence / Q000379:methods* / Q000592:standards; D006801:Humans; D009426:Netherlands; D019095:Point-of-Care Systems / Q000331:legislation & jurisprudence